184 related articles for article (PubMed ID: 14616939)
21. Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
De Laurentiis M; Cancello G; Zinno L; Montagna E; Malorni L; Esposito A; Pennacchio R; Silvestro L; Giuliano M; Giordano A; Caputo F; Accurso A; De Placido S
Ann Oncol; 2005 May; 16 Suppl 4():iv7-13. PubMed ID: 15923434
[TBL] [Abstract][Full Text] [Related]
22. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Pegram MD; O'Callaghan C
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
[TBL] [Abstract][Full Text] [Related]
23. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
24. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
26. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
27. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
[TBL] [Abstract][Full Text] [Related]
28. The development and clinical use of trastuzumab (Herceptin).
Harries M; Smith I
Endocr Relat Cancer; 2002 Jun; 9(2):75-85. PubMed ID: 12121832
[TBL] [Abstract][Full Text] [Related]
29. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.
Leonard DS; Hill AD; Kelly L; Dijkstra B; McDermott E; O'Higgins NJ
Br J Surg; 2002 Mar; 89(3):262-71. PubMed ID: 11872048
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Fornier M; Esteva FJ; Seidman AD
Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
[TBL] [Abstract][Full Text] [Related]
32. An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Gilewski T; Seidman A; Norton L; Hudis C
Cancer Chemother Pharmacol; 2000; 46 Suppl():S23-6. PubMed ID: 10950143
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
Pegram MD; Slamon DJ
Semin Oncol; 1999 Aug; 26(4 Suppl 12):89-95. PubMed ID: 10482199
[TBL] [Abstract][Full Text] [Related]
34. Moving forward: Herceptin in the adjuvant setting.
Tan-Chiu E; Piccart M
Oncology; 2002; 63 Suppl 1():57-63. PubMed ID: 12422056
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for metastatic breast cancer.
Biganzoli L; Minisini A; Aapro M; Di Leo A
Curr Opin Obstet Gynecol; 2004 Feb; 16(1):37-41. PubMed ID: 15128006
[TBL] [Abstract][Full Text] [Related]
36. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
37. Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer.
Lindrud S; Orlick M; Barnard N; Hait WN; Toppmeyer DL
Breast J; 2003; 9(2):116-9. PubMed ID: 12603385
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
39. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
40. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Lin A; Rugo HS
Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
